Browsing by Author "Güclü, F"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Macular edema in unregulated type 2 diabetic patients following glycemic control
    Kayykcyoolu, Ö; Özmen, B; Seymenoglu, G; Tunali, D; Kafesçiler, SO; Güclü, F; Hekimsoy, Z
    Background. We undertook this study to evaluate the changes in macular edema of uncontrolled type 2 diabetes mellitus patients with the regulation of hyperglycemia. Methods. The study population was comprised of 35 type 2 diabetes mellitus patients who had poorly regulated blood glucose values. Ophthalmic examinations including baseline and 6-month macular edema index values of patients by Heidelberg Retinal Tomography (HRT) macular module were done. Results. Twenty four (68.6%) female patients and 11 (31.4%) male patients with a mean age of 50.7 +/- 10.3 (mean +/- SD) years and mean diabetic duration of 9.8 +/- 7.5 years participated in the study. Twenty two (62.9%) did not have diabetic retinopathy (DR), whereas 13 (37.2%) had background DR with macular edema. There was a significant correlation between duration of diabetes and HRT-II macula edema index for the right and left eyes (r = 0.40, p = 0.21 and r = 0.40, p = 0.22, respectively). Conclusions. Macular edema did not change significantly by regulation of glycemic control in the study group. (C) 2007 IMSS. Published by Elsevier Inc.
  • No Thumbnail Available
    Item
    Glukagon like peptid-1
    Güclü, F; Özmen, B; Hekimsoy, Z; Kafesciler, SÖ
    Glucagon-like peptide-1 (GLP-1) is a 30 amino-acid hormone produced by the pancreatic islet alpha cells, intestinal-L cells and central nervous sytem cells. The main target of action of GLP-1 is the islet, where the hormone stimulates insulin secretion, promotes beta cell proliferation and neogenesis, and inhibits glucagon secretion. However, GLP-1 receptors are also expressed outside the islets, increasing the likelihood that GLP-1 also plays a role in other organs. These functions are mainly the inhibition of gastric emptying, gastric acid secretion and exocrine pancreatic secretion, indicating that the hormone acts as an enterogastrone hormone released from the distal portion of the small intestine that inhibits proximal gastrointestinal events. Another important action of GLP-1 is to induce satiety. Other effects of the hormone include cardioprotection, neuroprotection, induction of antidiabetic actions unrelated to islet function. Thus, GLP-1 clearly has several manifestations of activity. The physiological relevance of these actions and their contribution to the overall antidiabetic action of GLP-1 when used in treatment of type 2 diabetes remains to be established.